LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A compound based on the structure of kahalalide F according to formula 1:



(1)

wherein L-Orn at position 8 is substituted by another natural or non natural amino acid, and/or is masked with one or more substituent organic groups; and

wherein said compound may optionally differ from formula 1 by modification of the terminal acyl group; or a pharmaceutically acceptable salt thereof.

2-8. (Canceled)

9. (Previously presented) A compound according to claim 1, wherein the amino acid at position 8 is a masked L-Orn.

10. (Previously presented) A compound according to claim 1, wherein L-Orn at position 8 has been substituted by another natural or non-natural amino acid.

11. (Canceled)

12. (Previously presented) A compound according to claim 1, wherein the terminal acyl group is changed.

13. (Original) A compound according to claim 12, wherein the terminal acyl is 4(S)-methylhexyl.

14. (Canceled)

15. (Previously presented) A compound according to claim 1, based on the structure of kahalalide F of formula 1 designated KF, wherein said compound is selected from

[Glu^{8}]-KF,

[Lys^{8}]-KF,

[Lys^{8}, (4S)-$MeHex^{14}$]-KF,

[$N(Me)_2$,$N'(Me)_2$-Arg^{8}]-KF,

[N(Me,Ph),$N'(Me)_2$-Arg^{8}]-KF,

[$N(CH_2)_4$,$N'(Me)_2$-Arg^{8}]-KF,

[$N(CH_2)_4$,$N'(CH_2)_4$-Arg^{8}]-KF,

[$N\delta(CHN(CH_2)_4$-$N'(CH_2)_4)$-Orn^{8}]-KF,

[$N\varepsilon(Me)_3$-Lys^{8}, (4S)-$MeHex^{14}$]-KF,

[Orn(NδTFA)^{8}, (4S)-MeHex^{14}]-KF, and

[Orn(Biot)^{8}]-KF;

wherein the amino acid or group indicated between brackets is the modification introduced in the structure of kahalalide F, or a pharmaceutically acceptable salt thereof.

16. (Previously presented) A compound according to claim 9, wherein L-Orn at position 8 is masked with one or more substituents selected from the group consisting of alkyl groups and heterocyclic groups.

17. (Previously presented) A compound according to claim 10, wherein the L-Orn at position 8 has been substituted by D-Orn, or a masked natural amino acid.

18. (Previously presented) A compound according to claim 17, wherein the masked natural amino acid is arginine or lysine with one or more alkyl, phenyl or oligomethylene substituents.

19. (Previously presented) A compound according to claim 10, wherein the L-Orn at position 8 has been substituted by Glu or Lys.

20. (Previously presented) A compound according to claim 1, wherein the L-Orn at position 8 has been replaced by [N(Me)$_2$,N'(Me)$_2$-Arg], [N(Me,Ph),N'(Me)$_2$-Arg], [N(CH$_2$)$_4$,N'(Me)$_2$-Arg], [N(CH$_2$)$_4$,N'(CH$_2$)$_4$-Arg], [N$^{\delta}$(CHN(CH$_2$)$_4$,N'(CH$_2$)$_4$)-Orn], [N$^{\varepsilon}$(Me)$_3$-Lys], [Orn(N$^{\delta}$Tfa)], or [Orn(Biot)] and, optionally, 5-MeHex at position 14 has been replaced by (4S)-MeHex.

21. (Previously presented) A compound according to claim 1, wherein the terminal acyl group has been replaced by Icos, (c/t)-4-Me-cHexa, Und, (4R)-MeHex, (4RS)-MeHex, (4S)-MeHex, Oct, p-MeBza, Bza, p-CF$_3$Bza, 3,5-dFPhAc, Pipe, p-CF$_3$Cinn, p-CF$_3$PhAc, Pfh, 6-OHep, 6,6-dFHep, or 4-GuBut; and the L-Orn at position 8 has been replaced by L-Lys.

22. (Previously presented) A compound according to claim 1, wherein the terminal acyl group has been replaced by AM, AO, or $C(=N(CH_3)_2)$ and the L-Orn at position 8 has been replaced by L-Lys.

23. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, vehicle or diluent.

24. (Withdrawn) A method of treating a mammal affected by cancer which comprises administering to the affected individual a therapeutically effective amount of a compound according to claim 1.

25. (Withdrawn) The method of claim 24 wherein the mammal is a human.